BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25247335)

  • 1. The effect of IGF2BP2 gene polymorphisms on pioglitazone response in Chinese type 2 diabetes patients.
    Zhang LF; Pei Q; Yang GP; Zhao YC; Mu YF; Huang Q; Zhu YL
    Pharmacology; 2014; 94(3-4):115-22. PubMed ID: 25247335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.
    Huang Q; Yin JY; Dai XP; Pei Q; Dong M; Zhou ZG; Huang X; Yu M; Zhou HH; Liu ZQ
    Acta Pharmacol Sin; 2010 Jun; 31(6):709-17. PubMed ID: 20523342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replication of association study between type 2 diabetes mellitus and IGF2BP2 in Han Chinese population.
    Zhang SM; Xiao JZ; Ren Q; Han XY; Tang Y; Yang WY; Ji LN
    Chin Med J (Engl); 2013 Nov; 126(21):4013-8. PubMed ID: 24229666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between IGF2BP2 Polymorphisms and Type 2 Diabetes Mellitus: A Case-Control Study and Meta-Analysis.
    Rao P; Wang H; Fang H; Gao Q; Zhang J; Song M; Zhou Y; Wang Y; Wang W
    Int J Environ Res Public Health; 2016 Jun; 13(6):. PubMed ID: 27294943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of retinol binding protein 4 polymorphism on rosiglitazone response in Chinese type 2 diabetic patients.
    Zhou F; Huang Q; Dai X; Yin J; Wu J; Zhou H; Gong Z; Liu Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 36(10):949-57. PubMed ID: 22086013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of genetic polymorphisms of leptin and TNF-alpha on rosiglitazone response in Chinese patients with type 2 diabetes.
    Liu HL; Lin YG; Wu J; Sun H; Gong ZC; Hu PC; Yin JY; Zhang W; Wang D; Zhou HH; Liu ZQ
    Eur J Clin Pharmacol; 2008 Jul; 64(7):663-71. PubMed ID: 18438653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China.
    Pei Q; Huang Q; Yang GP; Zhao YC; Yin JY; Song M; Zheng Y; Mo ZH; Zhou HH; Liu ZQ
    Acta Pharmacol Sin; 2013 Feb; 34(2):255-61. PubMed ID: 23147557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus.
    Sheng FF; Dai XP; Qu J; Lei GH; Lu HB; Wu J; Xu XJ; Pei Q; Dong M; Liu YZ; Zhou HH; Liu ZQ
    Clin Exp Pharmacol Physiol; 2011 Aug; 38(8):550-4. PubMed ID: 21631570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.
    Hsieh MC; Lin KD; Tien KJ; Tu ST; Hsiao JY; Chang SJ; Lin SR; Shing SJ; Chen HC
    Metabolism; 2010 Aug; 59(8):1139-44. PubMed ID: 20045142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2.
    Dong M; Gong ZC; Dai XP; Lei GH; Lu HB; Fan L; Qu J; Zhou HH; Liu ZQ
    Clin Exp Pharmacol Physiol; 2011 Dec; 38(12):824-9. PubMed ID: 21933224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.
    Chappuis B; Braun M; Stettler C; Allemann S; Diem P; Lumb PJ; Wierzbicki AS; James R; Christ ER
    Diabetes Metab Res Rev; 2007 Jul; 23(5):392-9. PubMed ID: 17211855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of adiponectin allele 45T/G and -11377C/G polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients.
    Sun H; Gong ZC; Yin JY; Liu HL; Liu YZ; Guo ZW; Zhou HH; Wu J; Liu ZQ
    Br J Clin Pharmacol; 2008 Jun; 65(6):917-26. PubMed ID: 18429970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of NOS1AP rs12742393 polymorphism on repaglinide response in Chinese patients with type 2 diabetes mellitus.
    Wang T; Wang Y; Lv DM; Song JF; Lu Q; Gao X; Zhang F; Guo H; Li W; Yin XX
    Pharmacotherapy; 2014 Feb; 34(2):131-9. PubMed ID: 24338736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients.
    Huang Q; Yin JY; Dai XP; Wu J; Chen X; Deng CS; Yu M; Gong ZC; Zhou HH; Liu ZQ
    Eur J Clin Pharmacol; 2010 Dec; 66(12):1207-15. PubMed ID: 20809084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of association between single-nucleotide polymorphisms in lipid metabolism-related genes and type 2 diabetes mellitus in a Chinese population.
    Li Y; He S; Li C; Shen K; Yang M; Tao W; Yang Y; Shi L; Yao Y
    Int J Med Sci; 2021; 18(2):356-363. PubMed ID: 33390804
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes.
    Yang M; Huang Q; Wu J; Yin JY; Sun H; Liu HL; Zhou HH; Liu ZQ
    Br J Clin Pharmacol; 2009 Jul; 68(1):14-22. PubMed ID: 19659999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
    Sharma SK; Verma SH
    J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.